Lessons coming from a negative gene therapy trial for Duchenne muscle dystrophy

.Nature Medication, Released online: 09 October 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec got FDA permission after a bad test, which highlights the various difficulties and problems of medicine growth within this environment.